GLP-1 Agonist

Business

Hims & Hers Bets Big on Super Bowl Ad to Bridge Healthcare Gap and Investor Confidence

In a bold marketing move, telehealth company Hims & Hers is leveraging the Super Bowl's massive audience to spotlight healthcare inequality with its 'Rich People Live Longer' campaign. The push comes as the company expands into advanced diagnostics and treatments, while its stock navigates a significant valuation gap after recent volatility.

Business

Rhythm Pharmaceuticals: The Under-the-Radar Biotech Outpacing Tech Giants

While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.

Business

Eli Lilly Bets $3.5 Billion on Pennsylvania Plant, Doubling Down on Obesity Drug Future

Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.

Business

Insider Confidence: Three Global Growth Stocks Where Leadership Holds Major Stakes

Amidst a cautious market climate, companies with substantial insider ownership often signal strong internal conviction. We examine three such firms—spanning South Korean tourism, Chinese sensors, and Taiwanese biopharma—where executives and directors have significant skin in the game.

Business

Terns Pharma Secures Global Rights for Key Drug, Fueling Expansion Ambitions Beyond China

Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.

Business

Eli Lilly Doubles Down: $3.5 Billion Bet on Next-Gen Obesity Drugs and Gene Therapy Partnerships

Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Business

ResMed Posts Strong Q4 on Mask Innovation and Digital Health Surge, Beats Estimates

Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.

Business

Novo Nordisk Pivots: Oral Wegovy Launch, Job Cuts, and a Cell Therapy Bet Reshape Its Future

Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.

Business

Aon Posts Strong 2025, Eyes Steady Growth Amid Strategic Push

The global professional services firm reported sustained organic revenue growth and margin expansion for 2025, backed by its '3x3' strategic plan and technology investments. Leadership provided an upbeat outlook for 2026, targeting continued mid-single-digit growth and further profitability gains.

Business

Fast-Casual Dining Stocks Stage a Surprising Rebound Amid Shifting Consumer Habits

After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.